Physician profile
Michael Schachter
NPI 1588079727
$5,288.07
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $582 · 2021: $168 · 2022: $311 · 2023: $880 · 2024: $970 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Entertainment: $17.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.92 |
| Entertainment | $17.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,085.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $844.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $664.58 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $574.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $440.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $282.67 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $208.79 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $165.14 | 2019-2023 | |
| Amgen INC. | $134.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $118.68 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.66 | 2019-2020 | |
| Abbott Laboratories | $101.73 | 2019-2025 | Freestyle Libre 3 |
| Aytu Biopharma, INC. | $63.30 | 2019 | |
| Shire North American Group INC | $55.34 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.84 | 2024-2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.97 | 2019-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Amarin Pharma, INC. | $44.87 | 2019-2020 | |
| Lundbeck LLC | $31.09 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $28.72 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.80 | 2020 | |
| Allergan, INC. | $25.03 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.27 | 2019 | |
| Exact Sciences Corporation | $19.92 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $19.57 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $18.66 | 2023 | Xarelto |
| Genentech USA, INC. | $18.27 | 2019 | |
| Optos, INC. | $17.15 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bayer Healthcare Pharmaceuticals INC. | $16.61 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.42 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $13.55 | 2020 | |
| Boston Scientific Corporation | $13.54 | 2020 | |
| Medtronic Minimed, INC. | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schachter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.